With the launch of its two massively popular drugs for obesity and diabetes -- Ozempic and Wegovy -- Novo Nordisk seems to have started a biopharma gold rush. Now, companies across the world are racing to develop similar therapies to target these conditions, typically using the same scientific approach as Novo's molecule semaglutide, which is the basis for its rising new stars. 

Investors today have a plethora of different plays to choose from if they want exposure to the upside from this rapidly growing market. Let's take a look at two of the smaller competitors in biopharma that could stand to benefit hugely if they can commercialize a therapy in this space over the next few years. 

Image source: Getty Images.

Continue reading

Source Fool.com